Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$42.68 -1.2%	$37.30	$21.72 ▼ $45.48	$8.09B	1.11	2.49 million shs	1.89 million shs
BPMC Blueprint Medicines	$128.36 +0.1%	$110.15	$73.04 ▼ $128.52	$8.29B	0.84	1.31 million shs	2.03 million shs
MIRM Mirum Pharmaceuticals	$48.44 -4.8%	$45.72	$33.45 ▼ $54.23	$2.41B	0.95	464,856 shs	516,512 shs
MRNA Moderna	$28.86 +4.6%	$26.46	$23.15 ▼ $129.39	$11.15B	1.86	8.60 million shs	11.44 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-3.74%	+2.40%	+25.56%	+30.77%	+70.47%
BPMC Blueprint Medicines	+0.05%	-0.17%	+26.72%	+49.15%	+18.93%
MIRM Mirum Pharmaceuticals	-0.39%	+1.21%	+14.77%	+15.55%	+48.84%
MRNA Moderna	+1.58%	+7.48%	+3.88%	+1.58%	-76.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.706 of 5 stars	4.5	2.0	3.9	2.5	3.3	0.6
BPMC Blueprint Medicines	1.7456 of 5 stars	2.1	4.0	0.0	2.9	0.8	0.6
MIRM Mirum Pharmaceuticals	3.6196 of 5 stars	3.6	0.0	4.2	1.6	1.7	0.6
MRNA Moderna	4.3584 of 5 stars	4.0	2.0	4.6	1.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.93	Moderate Buy	$58.85	37.88% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.23% Downside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	35.22% Upside
MRNA Moderna	2.04	Hold	$46.61	61.52% Upside

Current Analyst Ratings Breakdown

Latest MIRM, MRNA, BPMC, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	36.52	N/A	N/A	($7.71) per share	-5.54
BPMC Blueprint Medicines	$508.82M	16.29	N/A	N/A	$4.70 per share	27.31
MIRM Mirum Pharmaceuticals	$336.89M	7.12	N/A	N/A	$4.70 per share	10.31
MRNA Moderna	$3.24B	3.45	N/A	N/A	$28.33 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.47	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)

Latest MIRM, MRNA, BPMC, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BPMC Blueprint Medicines	1.01	2.80	2.75
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
MRNA Moderna	N/A	4.22	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
MIRM Mirum Pharmaceuticals	N/A
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
MIRM Mirum Pharmaceuticals	22.87%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	38.21 million	Optionable
MRNA Moderna	3,900	386.74 million	344.20 million	Optionable

MIRM, MRNA, BPMC, and BBIO Headlines

Recent News About These Companies

Moderna flu shot outperforms marketed vaccines in pivotal late-stage trial

3 hours ago | thesiliconreview.comT

Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot

3 hours ago | biospace.comB

Moderna’s New Flu Shot Shows Strong Results in Older Adults

3 hours ago | usnews.com

Moderna Stock Gains on Encouraging Flu Vaccine Data

5 hours ago | zacks.com

The U.S. must invest in mRNA vaccines against pandemic influenza viruses now

July 1 at 8:03 AM | statnews.comS

Moderna flu vaccine shows superior results in phase 3 study

July 1 at 8:03 AM | pharmatimes.comP

13,644 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Diversified Trust Co

July 1 at 4:26 AM | marketbeat.com

Spire Wealth Management Sells 17,807 Shares of Moderna, Inc. (NASDAQ:MRNA)

July 1 at 3:55 AM | marketbeat.com

Pharmalittle: We’re reading about a Moderna flu vaccine, a J&J loss over 340B rebate plans, and more

July 1 at 3:02 AM | statnews.comS

Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Brokerages

July 1 at 2:47 AM | marketbeat.com

Moderna flu vaccine trial results clear path for combo shot

June 30 at 10:01 PM | beckershospitalreview.comB

Moderna shines spotlight on new flu vaccine data

June 30 at 5:01 PM | pharmaphorum.comP

Moderna’s flu vaccine hits goal, paving way for combo shot

June 30 at 5:01 PM | bostonglobe.comB

Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDA

June 30 at 5:01 PM | fiercebiotech.comF

Moderna’s mRNA flu shot outperforms current standard at Phase III

June 30 at 5:01 PM | finance.yahoo.com

Moderna flu shot outperforms marketed vaccines in large late-stage trial

June 30 at 5:01 PM | biopharmadive.comB

Experimental Moderna flu shot more effective than approved vaccine, company says

June 30 at 5:01 PM | msn.com

Moderna announces promising efficacy results from mRNA flu vaccine trial

June 30 at 5:01 PM | cidrap.umn.eduC

Moderna Stock Is Climbing on Trial Data. A Flu-Covid Vaccine Isn’t a Sure Thing.

June 30 at 5:01 PM | msn.com

Moderna, Inc. (MRNA) Opinions on Positive Flu Vaccine Trial Results

June 30 at 1:56 PM | quiverquant.comQ

Top Stock Movers Now: Hewlett Packard Enterprise, Moderna, Tesla, and More

June 30 at 12:00 PM | investopedia.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM, MRNA, BPMC, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$42.68 -0.50 (-1.16%)

As of 03:16 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$128.36 +0.18 (+0.14%)

As of 03:16 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Mirum Pharmaceuticals NASDAQ:MIRM

$48.44 -2.45 (-4.81%)

As of 03:16 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Moderna NASDAQ:MRNA

$28.86 +1.27 (+4.59%)

As of 03:16 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time